Biotechnology company specializing in development and commercialization of psychedelics therapeutics products Entheon Biomedical Corp. (CNSX: ENBI) (OTCQB: ENTBF) announced having secured a regulatory approval to start trading on the OTCQB Venture Market.
Chief executive officer of the company Timothy Ko, broke the news on May 5 further adding the company is now eligible to start trading on the market with immediate effect.
“We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science’s Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market,” said the CEO.
Shares of Enteon are now trading on the OTCQB under the ticker symbol ‘ENTBF’. The company’s shares will also continue trading on the Frankfurt Stock Exchange (FSE) as well as the Canadian Securities Exchange (CSE) using the ticker ‘ENBI’.
